April 2014
Reactions Weekly;Apr2014, Vol. 1497 Issue 1, p18
The article presents a case study of a 65-year-old female patient with wound sepsis which developed while receiving eculizumab for paroxysmal nocturnal haemoglobinuria (PNH) and with PNH flare that developed after eculizumab was discontinued.


Related Articles

  • Improvement of Renal Function by Long-Term Sustained Eculizumab Treatment in a Patient with Paroxysmal Nocturnal Hemoglobinuria. Ninomiya, Haruhiko; Obara, Naoshi; Niiori-Onishi, Akiko; Yokoyama, Yasuhisa; Sakata-Yanagimoto, Mamiko; Hasegawa, Yuichi; Chiba, Shigeru // Case Reports in Hematology;6/1/2015, Vol. 2015, p1 

    Chronic kidney disease (CKD) is one of the major manifestations of paroxysmal nocturnal hemoglobinuria (PNH). CKD in PNH is induced mainly by intravascular hemolysis of PNH-affected red blood cells (RBC) missing the glycosylphosphatidylinositol-anchored proteins with complement-regulatory...

  • Thrombotic complications without evidence of hemolysis in paroxysmal nocturnal hemoglobinuria: is eculizumab indicated? Bellido, M.; Velden, V.; Leebeek, F.; Boekhorst, P. // Annals of Hematology;Dec2012, Vol. 91 Issue 12, p1969 

    A case study is presented of a 30 year old man having history of auto-immune hepatitis developed pancytopenia and also focuses on the treatment of paroxysmal nocturnal hemoglobinuria (PNH). It informs that the treatment was conducted by using anticoagulant therapy with nadroparin and eculizumab...

  • Eculizumab injection.  // AHFS Consumer Medication Information;Aug2020, p1 

    Eculizumab injection is used to treat paroxysmal nocturnal hemoglobinuria (PNH: a type of anemia in which too many red blood cells are broken down in the body, so there are not enough healthy cells to bring oxygen to all parts of the body). Eculizumab injection is also used to treat atypical...

  • Eculizumab.  // Reactions Weekly;Apr2015, Vol. 1548 Issue 1, p98 

    The article presents a case study of an 18-year-old boy who developed meningococcaemia while receiving eculizumab drug for the treatment of paroxysmal nocturnal haemoglobinuria.

  • Long standing eculizumab treatment without anticoagulant therapy in high-risk thrombogenic paroxysmal nocturnal hemoglobinuria. Al-Jafar, Hassan A.; AlDallal, Salma M.; Askar, Haifa A.; Aljeraiwi, Ali M.; Al-Alansari, Ahmad // Hematology Reports;2015, Vol. 7 Issue 4, p63 

    Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-orphan disease affecting all hematopoietic cell types. The abnormality of red blood cells in this disease predisposes to intravascular complement-mediated hemolysis. Eculizumab is an orphan drug used to treat this rare disease. Thrombosis is...

  • Concerns about unapproved meningococcal vaccination for eculizumab therapy in Japan. Tetsuya Tanimoto; Eiji Kusumi; Kazutaka Hosoda; Kaduki Kouno; Tamae Hamaki; Masahiro Kami // Orphanet Journal of Rare Diseases;2014, Vol. 9 Issue 1, p2 

    An orphan medicinal product, eculizumab is approved in Japan and globally for treating paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Eculizumab therapy can cause late complement pathway deficiencies that predispose patients to meningococcal infections. Although...

  • Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. Wijnsma, Kioa Lente; ter Heine, Rob; Moes, Dirk Jan A. R.; Langemeijer, Saskia; Schols, Saskia E. M.; Volokhina, Elena. B.; van den Heuvel, Lambertus P.; Wetzels, Jack F. M.; van de Kar, Nicole C. A. J.; Br├╝ggemann, Roger J. // Clinical Pharmacokinetics;Jul2019, Vol. 58 Issue 7, p859 

    Eculizumab is the first drug approved for the treatment of complement-mediated diseases, and current dosage schedules result in large interindividual drug concentrations. This review provides insight into the pharmacokinetic and pharmacodynamic properties of eculizumab, both for reported...

  • PD65 The Acquisition Of Eculizumab By Judicial Proceeding In Brazil. Salomon, Flavia; Simabuku, Eliete; Beutel, Jose; Oliveira, Eduardo De; Rabelo, Roberta; Petramale, Clarice; de Brito, Artur Felipe; Souza, Kathiaja Miranda // International Journal of Technology Assessment in Health Care;2018 Supplement, Vol. 34, p153 

    Introduction: Eculizumab is a monoclonal antibody indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) or with atypical hemolytic uremic syndrome (aHUS). In Brazil in recent years eculizumab was the most expensive drug requested through court orders, obliging...

  • Eculizumab for paroxysmal nocturnal haemoglobinuria.  // PharmacoEconomics & Outcomes News;10/7/2006, Issue 513, p9 

    The article discusses research on the efficacy of eculizumab for treating patients with paroxysmal nocturnal haemoglobinuria, reference to a study by P. Hillmen and colleagues, published in the September 21, 2006 issue of the "New England Journal of Medicine." The hemoglobin level of eculizumab...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics